Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Monk

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
The Lancet. Respiratory Medicine|November 15, 2020
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trialPhillip D Monk, Richard J Marsden, Victoria J Tear, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|March 30, 2024
Transcranial Doppler cerebrovascular reactivity: Thresholds for clinical significance in cerebrovascular diseaseRobert W Regenhardt, Neal M Nolan, Alvin S Das, et al.
The European Respiratory Journal|December 7, 2013
Experimental rhinovirus 16 infection in moderate asthmatics on inhaled corticosteroidsPeter T Adura, Eleanor Reed, Jonathan Macintyre, et al.
Journal of Medical Genetics|August 3, 2004
Genomic imprinting of PPP1R9A encoding neurabin I in skeletal muscle and extra-embryonic tissuesK Nakabayashi, S Makino, S Minagawa, et al.
ERJ Open Research|March 30, 2023
Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III studyPhillip D Monk, Jody L Brookes, Victoria J Tear, et al.
Respiratory Research|May 29, 2024
Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPDPhillip D Monk, Jody L Brookes, Victoria J Tear, et al.
Brain : a Journal of Neurology|March 21, 2019
Neurological toxicities associated with chimeric antigen receptor T-cell therapyDaniel B Rubin, Husain H Danish, Ali Basil Ali, et al.
British Journal of Pharmacology|September 8, 2011
Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthmaR D May, P D Monk, E S Cohen, et al.
Eclinicalmedicine|October 19, 2023
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trialPrasanna Jagannathan, Kara W Chew, Mark J Giganti, et al.
Cell Reports. Medicine|August 22, 2024
Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2Joseph A Bell, Elizabeth R Davies, Christopher J Brereton, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
The Lancet. Respiratory Medicine|November 15, 2020
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trialPhillip D Monk, Richard J Marsden, Victoria J Tear, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|March 30, 2024
Transcranial Doppler cerebrovascular reactivity: Thresholds for clinical significance in cerebrovascular diseaseRobert W Regenhardt, Neal M Nolan, Alvin S Das, et al.
The European Respiratory Journal|December 7, 2013
Experimental rhinovirus 16 infection in moderate asthmatics on inhaled corticosteroidsPeter T Adura, Eleanor Reed, Jonathan Macintyre, et al.
Journal of Medical Genetics|August 3, 2004
Genomic imprinting of PPP1R9A encoding neurabin I in skeletal muscle and extra-embryonic tissuesK Nakabayashi, S Makino, S Minagawa, et al.
ERJ Open Research|March 30, 2023
Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III studyPhillip D Monk, Jody L Brookes, Victoria J Tear, et al.
Respiratory Research|May 29, 2024
Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPDPhillip D Monk, Jody L Brookes, Victoria J Tear, et al.
Brain : a Journal of Neurology|March 21, 2019
Neurological toxicities associated with chimeric antigen receptor T-cell therapyDaniel B Rubin, Husain H Danish, Ali Basil Ali, et al.
British Journal of Pharmacology|September 8, 2011
Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthmaR D May, P D Monk, E S Cohen, et al.
Eclinicalmedicine|October 19, 2023
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trialPrasanna Jagannathan, Kara W Chew, Mark J Giganti, et al.
Cell Reports. Medicine|August 22, 2024
Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2Joseph A Bell, Elizabeth R Davies, Christopher J Brereton, et al.
Pageof 10